Inflammatory Bowel Disease:
Drugs, Pipeline & Outstanding Targets

The figure below updates the seminal therapeutic target diagram of Neurath (2015, Nat Rev Gastroenterol Hepatol) to reflect eight additional mechanism approvals, a rich Phase 3 pipeline, and emerging undrugged targets. Nodes are colour-coded by development status; drug abbreviations appear beneath each target node. The three-layer architecture (innate activation → cytokine network → effector/trafficking) mirrors the biological cascade driving mucosal inflammation in IBD.

Conventional therapies (aminosalicylates, corticosteroids, immunomodulators) remain first- and second-line for mild-to-moderate IBD. Biological therapies blocking TNF-α transformed moderate-to-severe disease management from the late 1990s and continue to represent the most-prescribed advanced therapies globally, supplemented by an expanding biosimilar market. Vedolizumab (anti-α4β7) completed this pre-2015 era with a gut-selective mechanism that prefigured subsequent specificity-focused drug design.

Eight distinct mechanism approvals since 2015 have expanded the IBD therapeutic armamentarium into four entirely new target classes: IL-12/23, IL-23 p19, JAK/STAT, and S1P receptor. The convergence on IL-23 p19 inhibition — with three separate agents now approved — reflects its central role in Th17/ILC3 activation and the strong efficacy data from pivotal trials. The JAK inhibitor class offers rapid onset and broad cytokine blockade, while S1P modulators provide a gut-compartmentalized lymphocyte sequestration mechanism that avoids systemic immunosuppression. Guselkumab (Tremfya) is notable as the first fully-human, dual-acting mAb that also binds CD64 (FcγRI) on IL-23-producing cells.

The most significant emerging target is TL1A (TNFSF15) and its receptor DR3 — a TNF superfamily ligand strongly expressed in inflamed IBD mucosa that activates both T cells and ILC3s. Three distinct anti-TL1A antibodies are in Phase 3 trials simultaneously (tulisokibart/Merck, duvakitug/Teva-AbbVie, afimkibart/Pfizer), driven by compelling Phase 2 remission rates (32–48%) that exceed historical placebo-corrected responses for the target population. Notably, genetic variants near the TNFSF15 locus are among the most replicated IBD risk loci in GWAS studies, providing strong genomic validation.

Anti-MAdCAM-1 (ontamalimab) provides gut-selective lymphocyte trafficking blockade through a complementary mechanism to vedolizumab, and combination biologic approaches (DUET programme) are probing whether dual-pathway blockade can overcome the ~30–40% primary non-response rate that limits current monotherapies.

Despite significant therapeutic progress, approximately 30–50% of patients fail to achieve sustained remission on any single approved therapy, and many relapse after initial response. This therapeutic ceiling reflects the biological complexity of IBD — a disease driven by genetics, dysbiosis, epithelial barrier defects, innate immune activation, and stromal remodelling, none of which is fully addressed by any current drug. The targets below represent the most scientifically validated and clinically compelling unmet opportunities.

A consistent observation across all approved IBD biologics is a therapeutic ceiling: clinical remission rates in biologic-naïve patients rarely exceed 40–50% at one year, and prior biologic exposure further reduces response. This plateau reflects both the redundancy of cytokine networks (blocking one arm shifts inflammation to another) and the presence of non-immunological drivers such as barrier defects, dysmotility, and stromal remodelling.

Two complementary strategies are being pursued to break through this ceiling. The first is combination biologic therapy — exemplified by the VEGA Phase 2 trial (guselkumab + golimumab in UC), which showed 83% clinical response at week 12 vs 61% with golimumab alone. The DUET Phase 3 programme is now testing this principle at scale. The second strategy is biomarker-stratified precision medicine: identifying patients who are genomically or transcriptomically likely to respond to specific mechanisms (e.g. high mucosal OSM expression predicting anti-TNF non-response, TNFSF15 risk haplotype enriching TL1A responders).